ADC Therapeutics SA — Form 6-K Summary
Business context and reporting period
ADC Therapeutics SA, a Swiss biopharmaceutical company and foreign private issuer, filed this Form 6-K on November 7, 2023 for the month of November 2023. The filing reports a New York Stock Exchange (NYSE) continued-listing deficiency.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material change versus the prior comparable period
On October 10, 2023, the Company received notice from the NYSE that its common shares were not in compliance with the minimum share-price requirement under Section 802.01C of the NYSE Listed Company Manual. The requirement is a closing share price of at least $1.00 on average over a consecutive 30-trading-day period.
Outlook, risks, contingencies, and unusual items
- The Company has six months from receipt of the notice to regain compliance.
- The common shares remain listed and traded on the NYSE during the cure period, subject to compliance with other continued-listing requirements.
- Compliance may be regained if, on the last trading day of a calendar month during the cure period, the closing share price and the applicable 30-trading-day average closing price are each at least $1.00.
- The Company notified the NYSE of its intent to cure the deficiency. If necessary, it may pursue a reverse share split, subject to board and shareholder approval.
- The Company stated that there is no assurance it will regain compliance, satisfy other continued-listing requirements, or remain listed on the NYSE.
- Exhibit 99.1 is identified as a press release dated November 7, 2023, but its content is not included in the provided filing text.
Key facts for investors to verify
- Whether the Company regained compliance with the NYSE $1.00 minimum-price requirement within the six-month cure period.
- Whether a reverse share split was proposed, approved, or implemented.
- Whether the Company received any subsequent NYSE notices or faced additional listing deficiencies.
- The content of the November 7, 2023 press release referenced as Exhibit 99.1.